{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:10:08Z","timestamp":1746335408463,"version":"3.40.4"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Respiratory syncytial virus (RSV) infection is an important cause of hospitalization in infants and young children. Monthly administration of palivizumab during the RSV season is effective in preventing severe infections in children with comorbidities. However, determining the onset of the RSV season for starting palivizumab is often challenging. The present study aimed to evaluate the ideal timing to start palivizumab and its effect on hospitalization in the real world.<\/jats:p>\n            <jats:p>We performed a retrospective, observational study to identify the relationship between the timing of the first dose of palivizumab administration and RSV-related hospitalization. Medical records from 2015 to 2019 were reviewed. We included patients who had indications for palivizumab as of July 1 in each year. We counted the proportion of children receiving palivizumab and the number of RSV infection-related hospitalizations each month. We also evaluated the differences in background and underlying disease between children with and without hospitalization.<\/jats:p>\n            <jats:p>A total of 498 patients were included, and 105 (21.0%) completed the first dose in July when the RSV season usually begins in Japan. Twenty-three (4.6%) patients were hospitalized for RSV infection during the observation period, with 13 (56.5%) hospitalizations before their first dose of palivizumab. The remaining 10 patients were hospitalized after receiving 1 or more doses of palivizumab. Children living with siblings and children with cyanosis originating from congenital heart disease had a higher risk of RSV with odds ratios of 5.1 (95% confidence interval 1.48-17.6, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01) and 3.3 (95% confidence interval 1.33-7.94, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01), respectively.<\/jats:p>\n            <jats:p>Delays in administering palivizumab at the beginning of the season increases the rate of RSV infection-related hospitalization. To maximize prophylactic effectiveness, administering the first dose as early as possible in the RSV season is crucial, with priority for cyanotic children or those with siblings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027952","type":"journal-article","created":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T16:30:32Z","timestamp":1640795432000},"page":"e27952","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation"],"prefix":"10.1097","volume":"100","author":[{"given":"Akiko","family":"Kamori","sequence":"first","affiliation":[{"name":"Department of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Morooka","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Yamamura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin Fee","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Kuga","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Takahata","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Fukuoka Children's Hospital, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5224-6000","authenticated-orcid":false,"given":"Koichi","family":"Sagawa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, Fukuoka Children's Hospital, Fukuoka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-8348","authenticated-orcid":false,"given":"Kenji","family":"Furuno","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics and Interdisciplinary Medicine, Fukuoka Children's Hospital, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"R1-20250504","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","journal-title":"Am J Dis Child"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(99)80040-3","article-title":"Respiratory syncytial virus infection","volume":"354","author":"Simoes","year":"1999","journal-title":"Lancet"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0022-3476(95)70547-3","article-title":"Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection","volume":"126","author":"Wang","year":"1995","journal-title":"J Pediatr"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e20180225","DOI":"10.1542\/peds.2018-0225","article-title":"Down syndrome and the risk of severe RSV infection: a meta-analysis","volume":"142","author":"Beckhaus","year":"2018","journal-title":"Pediatrics"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1874285801105010144","article-title":"Risk factors for severe respiratory syncytial virus lower respiratory tract infection","volume":"5","author":"Sommer","year":"2011","journal-title":"Open Microbiol J"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ppul.23570","article-title":"Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis","volume":"52","author":"Stein","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamapediatrics.2014.3804","article-title":"Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection","volume":"169","author":"Gutfraind","year":"2015","journal-title":"JAMA Pediatr"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1080\/21645515.2017.1337614","article-title":"Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection","volume":"13","author":"Resch","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"R14-20250504","first-page":"CD006602","article-title":"Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children","volume":"4","author":"Andabaka","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/INF.0000000000001533","article-title":"Effectiveness of palivizumab in high-risk infants and children","volume":"36","author":"Anderson","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.pupt.2013.03.007","article-title":"Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis","volume":"26","author":"La Via","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fpubh.2019.00039","article-title":"Detection of the onset of the epidemic period of respiratory syncytial virus infection in Japan","volume":"7","author":"Yamagami","year":"2019","journal-title":"Front Public Health"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1017\/S0950268816002545","article-title":"Characterizing the risk of respiratory syncytial virus in infants with older siblings: a population-based birth cohort study","volume":"145","author":"Jacoby","year":"2017","journal-title":"Epidemiol Infect"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/archdischild-2015-308875","article-title":"Effectiveness of hand hygiene interventions in reducing illness absence among children in educational settings: a systematic review and meta-analysis","volume":"101","author":"Willmott","year":"2016","journal-title":"Arch Dis Child"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1800046","DOI":"10.2807\/1560-7917.ES.2019.24.1.1800046","article-title":"The contribution of child, family and health service factors to respiratory syncytial virus (RSV) hospital admissions in the first 3\u200ayears of life: birth cohort study in Scotland, 2009 to 2015","volume":"24","author":"Hardelid","year":"2019","journal-title":"Eurosurveill"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:30:20Z","timestamp":1746333020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027952"}},"subtitle":["A retrospective, observational study"],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":20,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027952","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"2021-02-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}